Carolina Madeira1, Miguel Lopes2, Rita Laiginhas3, João Neves4, Vitor Rosas1, Margarida Barbosa5, Davide Carvalho4, Fernando Falcão-Reis6, Manuel Falcão7. 1. Department of Ophthalmology, Centro Hospitalar e Universitário de São João, Porto, Portugal. 2. Faculty of Medicine, University of Porto, Portugal. 3. Department of Ophthalmology, Centro Hospitalar de Entre Douro e Vouga, Santa Maria da Feira, Portugal. 4. Faculty of Medicine, University of Porto, Portugal; Department of Endocrinology, Diabetes and Metabolism, Centro Hospitalar e Universitário de São João Porto, Portugal. 5. Department of Anesthesiology, Centro Hospitalar e Universitário de São João, Porto, Portugal. 6. Department of Ophthalmology, Centro Hospitalar e Universitário de São João, Porto, Portugal; Department of Surgery and Physiology, Faculty of Medicine of University of Porto, Portugal. 7. Department of Ophthalmology, Centro Hospitalar e Universitário de São João, Porto, Portugal; Department of Surgery and Physiology, Faculty of Medicine of University of Porto, Portugal. Electronic address: falcao@med.up.pt.
Abstract
PURPOSE: To estimate the prevalence of diabetic retinopathy /(DR) in a Portuguese population with type 1 diabetes (T1DM). METHODS: Retrospective review of all patients with T1DM, whose reference center was Centro Hospitalar de São João, a tertiary center in Portugal, who were diagnosed between 1990 and 2018. DR was classified based on fundus examination in medical records as (0) no evidence of retinopathy, (1) mild non-proliferative retinopathy (NPDR); (2) moderate to severe non-proliferative retinopathy (NPDR) and (3) proliferative retinopathy (PDR). Patients were classified according to the eye with a worse retinopathy stage. Follow-up was considered as time between the diagnosis of diabetes and the last funduscopic evaluation. RESULTS: 233 patients met the inclusion and exclusion criteria. The prevalence of any DR at less than 5, 10, 15, 20 and more than 20-years of DM was 1.8%, 10.4%, 34.8%, 54.1% and 71.2% respectively. The overall prevalence of DR was 43.3% (n = 101). At the last observation, 43 patients (18.5%) had mild NPDR, 34 patients (14.6%) had moderate to severe NPDR and 24 patients (10.3%) had PDR. The longer the disease duration, the higher the number of patients with DR. CONCLUSION: The prevalence of DR in our cohort was 34.8% after 15 years of systemic disease and 54.1% after 20 years, which is lower than what has been reported in the literature. Further multicentric prospective studies, are needed to clarify changes in the epidemiology of DR in type 1 diabetics.
PURPOSE: To estimate the prevalence of diabetic retinopathy /(DR) in a Portuguese population with type 1 diabetes (T1DM). METHODS: Retrospective review of all patients with T1DM, whose reference center was Centro Hospitalar de São João, a tertiary center in Portugal, who were diagnosed between 1990 and 2018. DR was classified based on fundus examination in medical records as (0) no evidence of retinopathy, (1) mild non-proliferative retinopathy (NPDR); (2) moderate to severe non-proliferative retinopathy (NPDR) and (3) proliferative retinopathy (PDR). Patients were classified according to the eye with a worse retinopathy stage. Follow-up was considered as time between the diagnosis of diabetes and the last funduscopic evaluation. RESULTS: 233 patients met the inclusion and exclusion criteria. The prevalence of any DR at less than 5, 10, 15, 20 and more than 20-years of DM was 1.8%, 10.4%, 34.8%, 54.1% and 71.2% respectively. The overall prevalence of DR was 43.3% (n = 101). At the last observation, 43 patients (18.5%) had mild NPDR, 34 patients (14.6%) had moderate to severe NPDR and 24 patients (10.3%) had PDR. The longer the disease duration, the higher the number of patients with DR. CONCLUSION: The prevalence of DR in our cohort was 34.8% after 15 years of systemic disease and 54.1% after 20 years, which is lower than what has been reported in the literature. Further multicentric prospective studies, are needed to clarify changes in the epidemiology of DR in type 1 diabetics.
Authors: Antonio J Martínez-Ortega; Cristina Muñoz-Gómez; Noelia Gros-Herguido; Pablo Jesús Remón-Ruiz; Domingo Acosta-Delgado; Fernando Losada-Viñau; Alfonso Pumar-López; Miguel Ángel Mangas-Cruz; Irene González-Navarro; Gema López-Gallardo; Virginia Bellido; Alfonso Manuel Soto-Moreno Journal: J Clin Med Date: 2022-02-17 Impact factor: 4.241